Lobbying Activity Report

3291-52672

This entry has been replaced by an amended Lobbying Activity Report: 3291-52793
Organization: AbbVie Corporation
Associated registration: 12221-3291-25
Lobbying Activity date: 2026-06-09
Arranged a meeting: Yes
Posted date: 2026-06-25

In-house lobbyists who participated in the lobbying activity: Jennifer Humphreys
Senior Public Office Holders who were lobbied in this activity: Susan Bouma, Executive Director
Therapeutic Assessment & Access, Health

John Capelli, Executive Director
Pharmaceutical Policy, Legislation & Engagement Branch, Health

Chris Ingram, Director
Therapeutic Assessment and Access Branch, Health

Sarah Pugh, Executive Director
Health

Ian Rongve, ADM
Health System Policy & Oversight, Health
 
Subject Matter of the Lobbying Activity
Specific Topics of Lobbying Communications Intended Outcomes Associated Subject Matters
AbbVie Corporation engages the British Columbia Government to advocate for policies that support timely access to AbbVie’s innovative medicines for appropriate patients. More specifically, we engage with government to: Advocate of the value of innovative pharmaceuticals in improving patient outcomes and overall savings to the healthcare system, as well as advancing health security and economic growth.
  • Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
 Advanced Education, Children and Families, Colleges & Universities, Economic Development and Trade, Finances and Budgets, Health, Indigenous Relations and Reconciliation, Mental Health and Addictions, Science and Technology, Senior Citizens
Advocate for pharmaceutical pricing and reimbursement policies that reflect the value of new medicines to patients and the health care system.
  • Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity
 Health
Help support health system improvements and healthcare outcomes.
  • Development or enactment of any regulation, including the enactment of a regulation for the purposes of amending or repealing a regulation
 Health, Mental Health and Addictions
 
Lobbying Activity Report replaced on: 2026-07-08 amended entry: 3291-52793
 
Senior officer who filed this Lobbying Activity Report: Tanusree Misra
 
The above name is that of the most senior paid officer who is responsible for filing a Lobbying Activity Report for the organization (the Designated Filer), whether that person participated in this lobbying activity or not.
Return to Registration for Organon Canada Inc. / Organon Canada inc.
Date Modified: